Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...

Q2 2025 Earnings Call Transcript August 13, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $ ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

Douglas was diagnosed with IV squamous cell carcinoma oral cancer, fearing he would have to have part of his jaw removed. The side effects of his treatment were horrific, with burns to his palate. He ...

Knocking down EPIC1 sensitized triple negative breast tumor-bearing mice to immunotherapy with the PD-1 inhibitor pembrolizumab.

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo versus sunitinib.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.